Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma
✍ Scribed by Grit Hutter; Miriam Scheubner; Yvonne Zimmermann; Joerg Kalla; Tiemo Katzenberger; Karin Hübler; Sabine Roth; Wolfgang Hiddemann; German Ott; Martin Dreyling
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 158 KB
- Volume
- 45
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Mantle cell lymphoma (MCL) is characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in overexpression of CCND1 in the vast majority of cases. In addition, alterations of other cell‐cycle‐regulating signal pathways (CDKN2B/CDKN2A‐CCND1 and ARF‐MDM2‐TP53) are frequently observed. However, the hierarchy of promoter methylations and genomic alterations as well as the interaction with other cell‐cycle regulator CDKN1A is poorly understood. A complete methylation‐specific PCR coupled with direct sequencing of 71 MCL patient samples previously characterized for TP53 alterations, Ki67 expression by immunohistochemistry, and other genomic alterations was performed. In contrast to rare p16(INK4a) promoter methylation (9%), frequent p15(INK4b) (62%) and p14(ARF) (70%) promoter methylation was detectable in MCL. In an additional 16% of MCL cases, LOH for p16(INK4a) was detected. However, MCL cases with p15(INK4b) methylation tended to have lower proliferation (73% vs. 57%), and p15(INK4b) and p14(ARF) promoter methylation was also detected in normal stem cells. Therefore, epigenetic changes of those genes seem not to represent primary oncogenic mechanisms but physiological mechanisms of cell regulation. The rare p16(INK4a) promoter methylation and p16(INK4a) genetic alterations were directly correlated to cell proliferation and therefore are regarded as additional molecular alterations involved in the cell‐cycle dysregulation of MCL. © 2005 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Background: It has been suggested that cyclin-dependent kinase inhibitors (cdkis), including p16 and p15, are tumor suppressor genes. alterations of cdkis have been found in most types of cancer. however, little is known about the status of p16 and p15 genes, including methylation of the promote
## Background: D-type cyclins, in association with the cyclin-dependent kinases cdk4 and cdk6, promote progression through the g1 phase of the cell cycle. cdk activity is modulated by inhibitors such as p15ink4b and p16ink4a. loss of function of p15ink4b and p16ink4a (multiple tumor suppressor-i an
The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alte